493 related articles for article (PubMed ID: 29578580)
1. MAO-B and COMT Genetic Variations Associated With Levodopa Treatment Response in Patients With Parkinson's Disease.
Sampaio TF; Dos Santos EUD; de Lima GDC; Dos Anjos RSG; da Silva RC; Asano AGC; Asano NMJ; Crovella S; de Souza PRE
J Clin Pharmacol; 2018 Jul; 58(7):920-926. PubMed ID: 29578580
[TBL] [Abstract][Full Text] [Related]
2. Association of COMT rs4680 and MAO-B rs1799836 polymorphisms with levodopa-induced dyskinesia in Parkinson's disease-a meta-analysis.
Yin Y; Liu Y; Xu M; Zhang X; Li C
Neurol Sci; 2021 Oct; 42(10):4085-4094. PubMed ID: 34346015
[TBL] [Abstract][Full Text] [Related]
3. The effect of monoamine oxidase B (MAOB) and catechol-O-methyltransferase (COMT) polymorphisms on levodopa therapy in patients with sporadic Parkinson's disease.
Białecka M; Droździk M; Kłodowska-Duda G; Honczarenko K; Gawrońska-Szklarz B; Opala G; Stankiewicz J
Acta Neurol Scand; 2004 Oct; 110(4):260-6. PubMed ID: 15355491
[TBL] [Abstract][Full Text] [Related]
4. Influence of single nucleotide polymorphisms in COMT, MAO-A and BDNF genes on dyskinesias and levodopa use in Parkinson's disease.
Cheshire P; Bertram K; Ling H; O'Sullivan SS; Halliday G; McLean C; Bras J; Foltynie T; Storey E; Williams DR
Neurodegener Dis; 2014; 13(1):24-8. PubMed ID: 24008922
[TBL] [Abstract][Full Text] [Related]
5. The catechol-O-methyltransferase and monoamine oxidase B polymorphisms and levodopa therapy in the Iranian patients with sporadic Parkinson's disease.
Torkaman-Boutorabi A; Shahidi GA; Choopani S; Rezvani M; Pourkosary K; Golkar M; Zarrindast MR
Acta Neurobiol Exp (Wars); 2012; 72(3):272-82. PubMed ID: 23093014
[TBL] [Abstract][Full Text] [Related]
6. The association of functional catechol-O-methyltransferase haplotypes with risk of Parkinson's disease, levodopa treatment response, and complications.
Bialecka M; Kurzawski M; Klodowska-Duda G; Opala G; Tan EK; Drozdzik M
Pharmacogenet Genomics; 2008 Sep; 18(9):815-21. PubMed ID: 18698234
[TBL] [Abstract][Full Text] [Related]
7. Long-term Effectiveness of Adjuvant Treatment With Catechol-O-Methyltransferase or Monoamine Oxidase B Inhibitors Compared With Dopamine Agonists Among Patients With Parkinson Disease Uncontrolled by Levodopa Therapy: The PD MED Randomized Clinical Trial.
Gray R; Patel S; Ives N; Rick C; Woolley R; Muzerengi S; Gray A; Jenkinson C; McIntosh E; Wheatley K; Williams A; Clarke CE;
JAMA Neurol; 2022 Feb; 79(2):131-140. PubMed ID: 34962574
[TBL] [Abstract][Full Text] [Related]
8. Association of Catechol-O-Methyltransferase and monoamine oxidase B gene polymorphisms with motor complications in parkinson's disease in a Chinese population.
Hao H; Shao M; An J; Chen C; Feng X; Xie S; Gu Z; Chan P;
Parkinsonism Relat Disord; 2014 Oct; 20(10):1041-5. PubMed ID: 25034874
[TBL] [Abstract][Full Text] [Related]
9. Gene polymorphisms and motor levodopa-induced complications in Parkinson's disease.
Michałowska M; Chalimoniuk M; Jówko E; Przybylska I; Langfort J; Toczylowska B; Krygowska-Wajs A; Fiszer U
Brain Behav; 2020 Mar; 10(3):e01537. PubMed ID: 32022467
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenetic profile and the development of the dyskinesia induced by levodopa-therapy in Parkinson's disease patients: a population-based cohort study.
Dos Santos EUD; da Silva IIFG; Asano AGC; Asano NMJ; De Mascena Diniz Maia M; de Souza PRE
Mol Biol Rep; 2020 Nov; 47(11):8997-9004. PubMed ID: 33151475
[TBL] [Abstract][Full Text] [Related]
11. Polymorphisms of Catechol-O-Methyl Transferase (COMT) Gene in Vulnerability to Levodopa-Induced Dyskinesia.
Ivanova SA; Alifirova VM; Pozhidaev IV; Freidin MB; Zhukova IA; Osmanova DZ; Zhukova NG; Mironova YA; Tiguntsev VV; Fedorenko OY; Bokhan NA; Wilffert B; Loonen AJM
J Pharm Pharm Sci; 2018; 21(1):340-346. PubMed ID: 30075828
[TBL] [Abstract][Full Text] [Related]
12. Pharmacologic treatment of advanced Parkinson's disease: a meta-analysis of COMT inhibitors and MAO-B inhibitors.
Talati R; Reinhart K; Baker W; White CM; Coleman CI
Parkinsonism Relat Disord; 2009 Aug; 15(7):500-5. PubMed ID: 19167259
[TBL] [Abstract][Full Text] [Related]
13. Genetic polymorphism of catechol-O-methyltransferase and levodopa pharmacokinetic-pharmacodynamic pattern in patients with Parkinson's disease.
Contin M; Martinelli P; Mochi M; Riva R; Albani F; Baruzzi A
Mov Disord; 2005 Jun; 20(6):734-9. PubMed ID: 15747357
[TBL] [Abstract][Full Text] [Related]
14. Polymorphisms of the dopamine metabolic and signaling pathways are associated with susceptibility to motor levodopa-induced complications (MLIC) in Parkinson's disease: a systematic review and meta-analysis.
Soraya GV; Ulhaq ZS; Shodry S; A'raaf Sirojan Kusuma M; Herawangsa S; Sativa MO; Gustaf A; Faridwazdi DAN; Florentia SW; Raisa N; Bintang AK; Akbar M
Neurol Sci; 2022 Jun; 43(6):3649-3670. PubMed ID: 35079903
[TBL] [Abstract][Full Text] [Related]
15. [Polymorphisms of catechol-O-methyltransferase and monoamine oxidase B genes among Chinese patients with Parkinson's disease].
Hao H; Shao M; An J; Chen C; Feng X; Xie S; Gu Z; Chen B
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2015 Feb; 32(1):1-5. PubMed ID: 25636089
[TBL] [Abstract][Full Text] [Related]
16. Association of Catechol-O-Methyltransferase Gene rs4680 Polymorphism and Levodopa Induced Dyskinesia in Parkinson's Disease: A Meta-Analysis and Systematic Review.
Dwivedi A; Dwivedi N; Kumar A; Singh VK; Pathak A; Chaurasia RN; Mishra VN; Mohanty S; Joshi D
J Geriatr Psychiatry Neurol; 2023 Mar; 36(2):98-106. PubMed ID: 35603896
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H
Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
[TBL] [Abstract][Full Text] [Related]
18. Association of monoamine oxidase B and catechol-O-methyltransferase polymorphisms with sporadic Parkinson's disease in an Iranian population.
Torkaman-Boutorabi A; Ali Shahidi G; Choopani S; Reza Zarrindast M
Folia Neuropathol; 2012; 50(4):382-9. PubMed ID: 23319194
[TBL] [Abstract][Full Text] [Related]
19. Genotypes of catechol-O-methyltransferase and response to levodopa treatment in patients with Parkinson's disease.
Lee MS; Lyoo CH; Ulmanen I; Syvänen AC; Rinne JO
Neurosci Lett; 2001 Feb; 298(2):131-4. PubMed ID: 11163295
[TBL] [Abstract][Full Text] [Related]
20. The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: a randomized crossover clinical trial.
Corvol JC; Bonnet C; Charbonnier-Beaupel F; Bonnet AM; Fiévet MH; Bellanger A; Roze E; Meliksetyan G; Ben Djebara M; Hartmann A; Lacomblez L; Vrignaud C; Zahr N; Agid Y; Costentin J; Hulot JS; Vidailhet M
Ann Neurol; 2011 Jan; 69(1):111-8. PubMed ID: 21280081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
